TABLE 4.

Extent of modification of A2058 and A2503 in clinical MRSA isolate CM05 and S. aureus RN4220 transformed with pMS2 or empty vector pLI50 before and after incubation with erythromycin or florfenicol

StrainSite% Modification after treatment witha:
No treatmentErythromycinFlorfenicol
RN4220(pLI50)A20581NDbND
A25030NDND
RN4220(pMS2)A2058122320
A250381116
CM05A2058343532
A2503252720
  • a The percentages shown were deduced from primer extension data and are the averages of at least two experiments.

  • b ND, not determined.